Darya D. Pozdnyakova

Darya D. Pozdnyakova

Auto-generated profile, based on publicly available information

Darya D. Pozdnyakova

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2021 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
LSL. V. Shogenova
L. V. Shogenova
TTThi Tuet Truong
Thi Tuet Truong
NKN. O. Kryukova
N. O. Kryukova
KYK. A. Yusupkhodzhaeva
K. A. Yusupkhodzhaeva
DPD. D. Pozdnyakova
D. D. Pozdnyakova
ACA. G. Chuchalin
A. G. Chuchalin
Active hydrogen inhalation (H(H2O)m) has powerful antioxidant and antiapoptotic effects. In recent years, it has been used in a number of experimental and clinical studies.Aim. To study the safety and effectiveness of inhalation of the “active form of hydrogen” (AFV;(H(H2O)m)) in the rehabilitation program of coronavirus disease 2019 (COVID-19) survivors during the recovery period.Material and methods. This randomized controlled parallel prospective study included 60 COVID-19 survivors with post-COVID-19 syndrome (ICD-10: U09.9) during the recovery period, with clinical manifestations of chronic fatigue syndrome (CFS), who received standard therapy in accordance with the management protocol of patients with CFS (ICD-10: G93.3): physiotherapy and medication therapy with drugs containing magnesium, B vitamins and L-carnitine. The patients were divided into 2 groups. The experimental group (n=30) included patients who received hydrogen inhalation for 90 minutes every day during 10 days (SUISONIA hydrogen inhalation device, Japan). The control group (n=30) consisted of patients who received standard therapy. In both groups, patients were comparable in sex and mean age: in the experimental group — 53 (22; 70) years, in the control group — 51 (25; 70) years. Biological markers of systemic inflammation, oxygen transport, lactate metabolism, intrapulmonary shunting, 6-minute walk test, and vascular endothelial function were determined in all patients on the 1st and 10th days of follow-up.Results. In the experimental group, a decrease in following parameters was revealed: stiffness index (SI), from 8,8±1,8 to 6,8±1,5 (p<0,0001); ALT, from 24,0±12,7 to 20,22±10,61 U/L (p<0,001); venous blood lactate, from 2,5±0,8 to 1,5±1,0 mmol/L (p<0,001); capillary blood lactate, from 2,9±0,8 to 2,0±0,8 mmol/L (p<0,0001); estimated pulmonary shunt fraction (Qs/Qt, Berggren equation, 1942) from 8,98±5,7 to 5,34±3,2 (p<0,01); white blood cells, from 6,64±1,57 to 5,92±1,32 109/L. In addition, we revealed an increase in the refractive index (RI) from 46,67±13,26% to 63,32±13,44% (p<0,0001), minimum blood oxygen saturation (SpO2) from 92,25±2,9 to 94,25±1, 56% (p<0,05), direct bilirubin from 2,99±1,41 to 3,39±1,34 pmol/L (p<0,01), partial oxygen tension (PvO2) from 26,9±5,0 to 34,8±5,6 mm Hg (p<0,0001), venous oxygen saturation (SvO2) from 51,8±020,6 to 61,1±018,1% (p<0,05), partial capillary oxygen tension (PcO2) from 48,7±15,4 to 63,8±21,2 mm Hg (p<0,01), capillary oxygen saturation (ScO2) from 82,2±4,2 to 86,2±4,8% (p<0,01), distance in 6 minute walk test from 429±45,0 to 569±60 m.Conclusion. Inhalation therapy with H(H2O)m in the rehabilitation program of COVID-19 survivors during the recovery period is a safe and highly effective method. Manifestations of silent hypoxemia and endothelial dysfunction decreased, while exercise tolerance increased. As for laboratory tests, a decrease in the white blood cell count, estimated pulmonary shunt fraction and lactate content parameters was revealed.

16 April 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
DPD D Pozdnyakova
D D Pozdnyakova
TBT А Bakhareva
T А Bakhareva
IBIrina Baranova
Irina Baranova
VSV D Selemir
V D Selemir
ACAlexander Chuchalin
Alexander Chuchalin
Рost-COVID-19 syndrome (PS) is one of the medical and social problem. According to WHO, 10–20% of COVID-19 patients suffer from PS. The use of medical gases – inhaled nitric oxide (iNO) and molecular hydrogen (iH2) – may influence on the mechanisms of development PC. Aim. To evaluate the safety and efficacy of the combined inhalation of NO and H2 (iNO/iH2) in patients with respiratory manifestations of PS. Materials and methods. 34 patients with PS (11 men/23 women, 60.0±11.7 years) were included in the prospective open-label controlled study in parallel groups: the main group (n=17) received iNO/iH2 for 90 minutes once a day for 10 days (concentration of NO 60 ppm, H24% in the gas mixture), the control group (n=17) didn’t receive inhalations. The period from the confirmation of COVID-19 to the start of the study was 641.8±230.5 days. The groups did not differ in the baseline parameters. The clinical symptoms (from the self-observation diary and mMRC questionnaires, "dyspnea language"), FAS, HADS, SF-36 scores, 6-minute walk test, the blood serum parameters of oxidative stress, the dynamics of the microcirculation in the eye bulbar conjunctiva were evaluated. The individual dose of iNO has chosen during a 15-minute test (the positive dynamics of the microcirculation have indicated that the dose was selected correctly). Results. The decrease the symptoms severity, such as dyspnea, cough, fatigue and palpitations (p0.005), the increase in SF-36 questionnaire scores (p=0.006) and a reducing of FAS score (p=0.001), as well as the anxiety component of HADS (p=0.02) were revealed at the end of treatment in the main group compared to the control group. We observed an improvement in distance walked (p=0.01) and the values SpO2 (p=0.04) in 6-minute walk test, the increase in the volumetric blood flow velocity in venules (p0.001), and the date in oxidative damage (p0.001) and antioxidant activity (p=0.03) parameters in the blood serum. Conclusion. The results of the study demonstrate clinical efficacy iNO/iH2 on clinical indicators, parameters of oxidative stress and microcirculation in patients with PS.

9 February 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
HNH. C. Nguyen
H. C. Nguyen
DPD. D. Pozdnyakova
D. D. Pozdnyakova
IBIrina Baranova
Irina Baranova
ACAlexander Chuchalin
Alexander Chuchalin
ХНХ. К. Нгуен
Х. К. Нгуен
Inhaled nitric oxide (iNO) is being considered as a potential therapeutic intervention for COVID-19 and post-COVID syndrome due to its various mechanisms such as vasodilation, antiviral activity, antithrombotic and anti-inflammatory effects. There is currently a lack of information on patient selection criteria, optimal dosing, duration and timing of administration, and methods of administration. These factors are of substantial importance for the efficacy of iNO therapy.Aim. To discuss the physiological basis of using inhaled nitric oxide for treating patients with COVID-19 and post- COVID syndrome, analyze the research findings, and present the achievements in nitric oxide synthesis technology in medicine.Conclusion. The early initiation and use of high-dose iNO appears to be an effective and safe treatment strategy for patients with COVID-19, as it targets the basic pathological mechanisms of the disease. iNO may also be a promising therapeutic option for patients with post-COVID syndrome. However, the optimal dosing regimen, continuous or intermittent, warrants further investigation. Recent advances in nitric oxide synthesis technology are of great significance for the broad practical application of iNO therapy.

13 January 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
DPD. D. Pozdnyakova
D. D. Pozdnyakova
IBIrina Baranova
Irina Baranova
VSV. D. Selemir
V. D. Selemir
ACAlexander Chuchalin
Alexander Chuchalin
Inhaled nitric oxide (NO) and molecular hydrogen (iH2) are actively studied nowadays. The therapeutic algorithms for their use in the various conditions are being developed, but the combined use of these medical gases (MG) has not been studied well enough.The aim of the study was to assess the safety of iNO and iH2 combination in healthy volunteers.Methods. 10 healthy volunteers (4 males and 6 females), mean age 24.0 ± 1.3 years, were included in the open non-comparative prospective study. All volunteers received a single combined inhalation of NO and H2 for 90 minutes. The NO concentration was 60 ppm and the H2 concentration did not exceed 4% in the gas mixture. Changes in the vital signs, arterial blood gases, and hemodynamic parameters were evaluated. The hemodynamic parameters were investigated before and after inhalation using echocardiography (Vivid E9 General Electric, USA). We also assessed the microcirculation of the bulbar conjunctiva (“OKO” capillaroscope), the main functional lung parameters, and the diffusion lung capacity (GANSHORN PowerCube Body apparatus). The clinical side effects were recorded. After inhalation, the serum concentration of methemoglobin was evaluated.Results. When comparing the results before and after MG inhalation, there was no negative impact on the vital signs, arterial blood gases (РaO2, РaСO2, SаO2), the functional lung volumes (FEV1, FVC, FEV1 / FVC), the diffusion test parameters, main EchoCG hemodynamic data (ejection fraction, tricuspid annular plane systolic excursion (TAPSE), mean pulmonary artery pressure, left and right ventricular sizes) (p > 0,05). After inhalation, the microcirculatory parameters (the volume velocity in arterioles and venules and the arteriolar diameter) increased significantly (p < 0.05). We did not observe the increase in serum methemoglobin concentration (0.59 ± 0.11%). No clinical side effects were reported during the study.Conclusions. Combined use of inhaled NO / H2 is clinically safe, does not have any negative impact on hemodynamic parameters, functional lung volumes, and arterial blood gases. The improvement of the microcirculation was noted after a single inhalation. This new method can be recommended for further studies of the therapeutic effect in various conditions.

17 March 2026 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
DPDarya D. Pozdnyakova
Darya D. Pozdnyakova
IBIrina Baranova
Irina Baranova
VSVictor D. Selemir
Victor D. Selemir
OMOleg Stephanovich Medvedev
Oleg Stephanovich Medvedev
ACAlexander Chuchalin
Alexander Chuchalin
ПДПозднякова Дарья Дмитриевна
Позднякова Дарья Дмитриевна
Background. Medical gases, inhaled nitric oxide (iNO) and molecular hydrogen (iH2), have been used in the therapy for various medical conditions. When combined, these gases have shown to be more effective and safer for patients, and may become a promising treatment option for various diseases рost-COVID-19 syndrome (PS). Aim. To compare the efficacy and safety of combined therapy iNO/iH2 with monotherapy iNO and a control group in patients with respiratory disorders during with PS. Materials and methods. A prospective, open-label, controlled trial involving 60 patients with PS was conducted in parallel groups (the mean age of the participants was 58.1 ± 12.9 years, and the sample consisted of 18 men and 42 women). The participants were randomly assigned to 3 groups: 1 (n = 20) – iNO/iH2 treatment; 2 (n = 20) – only iNO treatment; and 3 (n = 20) – control group. The duration of treatment was 10 days, and the treatment involved inhalation through a nasal cannula for 90 minutes (flow rate of 4 liters per minute, iH2 concentrations 4%, iNO – 60 pmm). Clinical outcomes were assessed using self-observation diaries, Modified Medical Research Council Dyspnea Scale questionnaires, the "Language of Dyspnea" Scale, Fatigue Assessment Scale, Hospital Anxiety and Depression Scale, and Short Form-36 Health Status Survey questionnaires. Additionally, a 6-Minute Walk Test was performed, and indicators of oxidative status in blood serum and microcirculation in the bulbar conjunctiva were measured. Results. The course of iNO/iН2 and iNO led to regression of the clinical manifestations of PS (dyspnea, cough, fatigue), improved the physical and psychological component of quality of life, and contributed to improvement in microcirculation (increased venule diameter and velocity) compared to the control group (p 0.05). In combination therapy, there was an increase in distance traveled by 6-minute walk test and decrease in reactive oxygen species compared to iNO and control groups (p 0.05). No serious adverse events were noted. Conclusion. The study demonstrates the advantage of the iNO/iH2 course in comparison with iNO and control in the rehabilitation program of patients with PS. The safety and effectiveness of the iNO/iH2 course has been proven in the form of regression of clinical manifestations of PS, improvement of quality of life, exercise tolerance, microcirculation parameters, and restoration of the oxidative status of the body.